POIETIS

Their core work

POIETIS is a French biotech SME specializing in 3D bioprinting — the technology of printing living cells and tissues layer by layer. Based in Pessac (near Bordeaux), they provide bioprinting expertise to EU research consortia developing tissue models for disease research and regenerative medicine. Their work spans printing brain tissue models, pancreatic tissue for disease studies, and complex joint implants, positioning them as a go-to bioprinting partner for biomedical applications across Europe.

What they specialise in

How they've shifted over time

POIETIS entered H2020 in 2018 with foundational bioprinting work — printing brain-on-chip models (ASCTN-Training) and pancreatic tissue for disease research (Pan3DP). By 2020, their focus shifted decisively toward clinical translation: JOINTPROMISE brought in robotics, bioreactors, large animal models, and manufacturing scale-up for joint implants classified as Advanced Therapy Medicinal Products (ATMPs). The trajectory is clear — from printing research-grade tissue models to manufacturing implantable medical products.

POIETIS is transitioning from a research bioprinting provider to a manufacturing-oriented partner capable of producing regulatory-grade implants, making them increasingly relevant for translational medicine and ATMP development projects.

How they like to work

POIETIS operates exclusively as a specialist participant — they have never coordinated an H2020 project, instead contributing their bioprinting technology to consortia led by others. Despite only three projects, they have worked with 20 unique partners across 10 countries, suggesting they are sought after as a specialized technology provider rather than building a fixed circle of repeat collaborators. This profile is typical of a technology SME that brings a distinctive capability to diverse research teams.

POIETIS has built a broad European network of 20 partners across 10 countries through just 3 projects, indicating high connector value per project. Their partnerships span academic and clinical partners across Western and Southern Europe, reflecting the interdisciplinary nature of bioprinting consortia.

What sets them apart

POIETIS occupies a rare niche as a dedicated bioprinting SME — most bioprinting expertise in H2020 sits inside universities, while POIETIS brings an industry perspective focused on reproducibility and manufacturing scale-up. Their progression from tissue modelling to ATMP-grade implant production means they can bridge the gap between academic proof-of-concept and industrial production. For consortium builders, they offer something hard to find: a private-sector bioprinting partner with hands-on experience in both research prototyping and manufacturing pathway design.

Highlights from their portfolio

• JOINTPROMISE
  Their largest project (EUR 1.1M, 64% of total funding) targeting precision-manufactured joint implants — represents their strategic shift toward clinical-grade manufacturing with robotics and bioreactor integration.
• Pan3DP
  Focused specifically on 3D bioprinting of pancreatic tissue, combining developmental biology with disease modelling — a technically demanding application demonstrating deep bioprinting competence.
• ASCTN-Training
  An MSCA training network on advanced stem cell technologies in neurology, showing POIETIS contributes to workforce training alongside R&D — useful for their credibility as a knowledge hub.